National Immunisation Schedule
From 1 July 2017: Update coming soon
| Vaccine | Brand Name | Scheduled Event | Route | New/Replaces | |
|---|---|---|---|---|---|
| 1. | Rotavirus vaccine (RV) | Rotarix | 6 weeks, 3 months | Oral | Replaces 3 dose regimen of Rotateq at 6 weeks, 3 months and 5 months. |
| 2. | 10-valent pneumococcal vaccine (PCV10) | Synflorix | 6 weeks, 3, 5, & 15 months | IM | Replaces 13-valent pneumococcal conjugate vaccine (PCV13, Prevenar 13) event at 6 weeks, 3, 5, and 15 months^ |
| 3. | Varicella vaccine (VV) | Varilrix | 15 months or 11 years if not previously vaccinated or infected* | SC | New on schedule |
| 4. | MMR (measles, mumps and rubella) | Priorix | 15 months, 4 years | SC | Replaces MMR-II |
| 5. | Haemophilus influenzae type b (Hib) | Hiberix | 15 months | IM | Replaces Act-Hib |
Funding criteria for high-risk patients will remain unchanged.
^Prevenar 13 will remain available for high-risk patients only.
*Varicella vaccine will be funded for children born on or after 1 April 2016, at their 15 month immunisation event, and children who turn age 11 years on or after 1 July 2017 if they have not previously been infected with chickenpox or vaccinated.
The Immunisation Advisory Centre has produced a short video explaining the changes.
| Age | Diseases covered and vaccines |
|---|---|
| 6 weeks | Rotavirus (start first dose before 15 weeks) 1 oral vaccine (RotaTeq®) |
| Diphtheria/Tetanus/Pertussis/Polio/Hepatitis B/Haemophilus influenzae type b 1 injection (INFANRIX® -hexa) |
|
| Pneumococcal 1 injection (PREVENAR 13®) |
|
| 3 months | Rotavirus 1 oral vaccine (RotaTeq®) |
| Diphtheria/Tetanus/Pertussis/Polio/Hepatitis B/Haemophilus influenzae type b 1 injection (INFANRIX® -hexa) |
|
| Pneumococcal 1 injection (PREVENAR 13®) |
|
| 5 months | Rotavirus 1 oral vaccine (RotaTeq®) |
| Diphtheria/Tetanus/Pertussis/Polio/Hepatitis B/Haemophilus influenzae type b 1 injection (INFANRIX® -hexa) |
|
| Pneumococcal 1 injection (PREVENAR 13®) |
|
| 15 months | Haemophilus influenzae type b 1 injection (Act-HIB) |
| Measles/Mumps/Rubella 1 injection (M-M-R® ll) |
|
| Pneumococcal 1 injection (PREVENAR 13®) |
|
| 4 years | Diphtheria/Tetanus/Pertussis/Polio 1 injection (INFANRIX™-IPV) |
| Measles/Mumps/Rubella 1 injection (M-M-R® ll) |
|
| 11 years | Tetanus/Diphtheria/Pertussis 1 injection (BOOSTRIX™) |
| 12 years | Human papillomavirus 2 doses given at least 6 months apart (GARDASIL®9) |
| 45 years | Diphtheria/Tetanus 1 injection (ADT™ Booster) |
| 65 years | Diphtheria/Tetanus 1 injection (ADT™ Booster) |
| Influenza 1 Injection (annually) |
http://www.immune.org.nz/vaccines
National Immunisation Schedule
Vaccines
All vaccines available in New Zealand are licensed for use in this country.
Vaccines on the New Zealand National Immunisation Schedule are free when given as part of the Schedule. Other vaccines are not funded, but are available for purchase through your family doctor.
Last updated: 27-04-2017
Varilrix® is used for primary vaccination of infants from nine months of age, children and adults to protect against varicella-zoster infection (chickenpox). The vaccine may prevent or reduce the severity of chickenpox disease if it is given within 3-5 days of exposure to someone with the disease.
A two dose course of Varilrix® is recommended and funded for individuals aged 9 months or older who have not have the disease or immunisation and who meet at least one of the eligibility criteria below:
- Who are HIV-positive with mild or moderate immunosuppression, on the advice of their specialist
- Prior to elective immunosuppressive therapy that will be longer than 28 days
- With chronic liver disease who may in future be candidates for transplantation
- With deteriorating renal function before transplantation
- Prior to solid organ transplantation
- After a haematopoietic stem cell transplantation, on the advice of their specialist
- After chemotherapy, on the advice of their specialist
- With an inborn error of metabolism at risk of major metabolic decompensation,
- Who are a household contact of a child or adult patient who is immunocompromised or undergoing a procedure leading to immunocompromise, where the household contact has no clinical history of varicella infection of immunisation